Literature DB >> 18348660

Prevalent expression of MHC class I chain-related molecule A in human osteosarcoma.

Shan-ming Lu1, Ping Xiao, Ling Xue, Li-hong Che, Ping Yang, Yang Li, Hui Qiao.   

Abstract

MHC class I chain-related molecule A (MICA) is one of the major ligands for activating immune-receptor NKG2D which is expressed on NK cells and cytotoxic T lymphocytes. The release and sustained expression of MICA protein can impair NKG2D-mediated cytotoxic activity by reducing NKG2D receptor on immune effector cells. The aim of the study was to investigate the expression and release of MICA in human osteosarcoma. RT-PCR, immunohistochemistry, western blotting and flow cytometry were used in analyzing the expression of MICA. Serum level of soluble MICA was quantitated by ELISA. Our data showed that MICA is prevalently expressed in osteosarcoma both in mRNA and protein level. Upregulation of MICA was found in osteosarcoma compared with benign tumors and normal bone tissues. Higher level of soluble MICA in serum can be detected in osteosarcoma patients. In conclusion, prevalent expression of MICA and higher serum level of soluble MICA may suggest a deficiency of MICA-NKG2D mediated immunosurveillance in osteosarcoma patients. Restoring the expression of NKG2D receptor on immune effector cells may contribute to a therapeutic strategy for human osteosarcoma.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18348660

Source DB:  PubMed          Journal:  Neoplasma        ISSN: 0028-2685            Impact factor:   2.575


  7 in total

1.  Effect of entinostat on NK cell-mediated cytotoxicity against osteosarcoma cells and osteosarcoma lung metastasis.

Authors:  Simin Kiany; Gangxiong Huang; Eugenie S Kleinerman
Journal:  Oncoimmunology       Date:  2017-07-11       Impact factor: 8.110

Review 2.  Natural Killer Cell Immunotherapy for Osteosarcoma.

Authors:  Brian P Tullius; Buhvana A Setty; Dean A Lee
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

3.  Diagnostic and prognostic impact of serum-soluble UL16-binding protein 2 in lung cancer patients.

Authors:  Kosuke Yamaguchi; Hiroki Chikumi; Asuka Shimizu; Miyako Takata; Naoki Kinoshita; Kiyoshi Hashimoto; Masaki Nakamoto; Shinji Matsunaga; Jun Kurai; Naomi Miyake; Shingo Matsumoto; Masanari Watanabe; Akira Yamasaki; Tadashi Igishi; Naoto Burioka; Eiji Shimizu
Journal:  Cancer Sci       Date:  2012-07-10       Impact factor: 6.716

Review 4.  Innate Immune Cells: A Potential and Promising Cell Population for Treating Osteosarcoma.

Authors:  Zenan Wang; Zhan Wang; Binghao Li; Shengdong Wang; Tao Chen; Zhaoming Ye
Journal:  Front Immunol       Date:  2019-05-16       Impact factor: 7.561

Review 5.  Prospects for NK Cell Therapy of Sarcoma.

Authors:  Mieszko Lachota; Marianna Vincenti; Magdalena Winiarska; Kjetil Boye; Radosław Zagożdżon; Karl-Johan Malmberg
Journal:  Cancers (Basel)       Date:  2020-12-11       Impact factor: 6.639

6.  Natural Killer Dendritic Cells Enhance Immune Responses Elicited by α -Galactosylceramide-Stimulated Natural Killer T Cells.

Authors:  Sung Won Lee; Hyun Jung Park; Nayoung Kim; Seokmann Hong
Journal:  Biomed Res Int       Date:  2013-06-26       Impact factor: 3.411

Review 7.  T-Cell-Based Immunotherapy for Osteosarcoma: Challenges and Opportunities.

Authors:  Zhan Wang; Binghao Li; Yingqing Ren; Zhaoming Ye
Journal:  Front Immunol       Date:  2016-09-14       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.